A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Links
- BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting FDA Safety Alerts and Recalls Investigator Inquiry Form
- ID
- NCT04674813
- Phase
- Phase 1 Multiple Myeloma Research Study
- Study Type
- Interventional
- Participants
- Expecting 180 study participants
- Last Updated